文献速递临床试验与 GCP

肌内或静脉注射氨甲环酸预防高危产妇产后出血:一项随机安慰剂对照试验(I'M WOMAN)

Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I'M WOMAN).
PubMed 文献 · Trials · 2023-12-03

I'M WOMAN试验是一项国际多中心、三臂、随机双盲安慰剂对照试验,评估肌内与静脉注射氨甲环酸预防产后出血的效果。研究对象为具有至少一项产后出血危险因素且经阴道分娩或剖宫产分娩的产妇。该试验旨在提供氨甲环酸预防产后出血的获益与危害证据,以及肌内与静脉给药途径的效果差异。

要点

  • 产后出血每年导致约7万例孕产妇死亡,静脉氨甲环酸在分娩后3小时内给药可使产后出血死亡减少三分之一。
  • 肌内注射氨甲环酸耐受良好且吸收迅速,注射后数分钟内可达治疗性血药浓度。
  • 该试验为国际多中心、三臂、随机双盲安慰剂对照试验,评估肌内与静脉氨甲环酸预防产后出血。

核心结论

  • 该试验将提供氨甲环酸预防产后出血的获益与危害证据,以及肌内与静脉给药途径的效果差异。
  • 肌内途径预防出血应和静脉途径一样有效。
  • 肌内氨甲环酸副作用可能更少,因为其血药峰浓度低于静脉途径。
  • 肌内氨甲环酸具有实践优势,给药更快速简便,可避免静脉置管和缓慢静脉注射的需要,从而释放紧张的助产士和医生人力以专注于照护母婴,并扩大及时氨甲环酸治疗的覆盖面。

研究设计与样本

  • I'M WOMAN试验为国际、多中心、三臂、随机、双盲、安慰剂对照试验。
  • 研究对象为具有一项或以上产后出血危险因素、经阴道分娩或剖宫产分娩的产妇。
  • 试验评估肌内与静脉氨甲环酸预防产后出血的效果。

局限性

  • 原文报告产后出血仅影响小部分分娩,在将氨甲环酸用于预防产后出血之前需要良好的获益与危害平衡证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postpartum haemorrhage (PPH) causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a life-saving treatment for women with PPH. Intravenous (IV) TXA reduces deaths due to PPH by one-third when given within 3 h of childbirth. Because TXA is more effective when given early and PPH usually occurs soon after childbirth, giving TXA just before childbirth might prevent PPH. Although several randomised trials have examined TXA for PPH prevention, the results are inconclusive. Because PPH only affects a small proportion of births, we need good evidence on the balance of benefits and harms before using TXA to prevent PPH. TXA is usually given by slow IV injection. However, recent research shows that TXA is well tolerated and rapidly absorbed after intramuscular (IM) injection, achieving therapeutic blood levels within minutes of injection. METHODS: The I'M WOMAN trial is an international, multicentre, three-arm, randomised, double-blind, placebo-controlled trial to assess the effects of IM and IV TXA for the prevention of PPH in women with one or more risk factors for PPH giving birth vaginally or by caesarean section. DISCUSSION: The trial will provide evidence of the benefits and harms of TXA for PPH prevention and the effects of the IM and IV routes of administration. The IM route should be as effective as the IV route for preventing bleeding. There may be fewer side effects with IM TXA because peak blood concentrations are lower than with the IV route. IM TXA also has practical advantages as it is quicker and simpler to administer. By avoiding the need for IV line insertion and a slow IV injection, IM administration would free up overstretched midwives and doctors to focus on looking after the mother and baby and expand access to timely TXA treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT05562609. Registered on 3 October 2022. ISRCTN Registry ISRCTN12590098. Registered on 20 January 2023. Pan African Clinical Trial Registry PACTR202305473136570. Registered on 18 May 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Brenner A, Shakur-Still H, Chaudhri R, et al. Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I'M WOMAN). Trials. 2023. PMID: 38044460. doi:10.1186/s13063-023-07687-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。